Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism EZH2 inhibitors(Histone-lysine N-methyltransferase EZH2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC36H46N6O3 |
InChIKeyJQCQAOKPLACZCY-UHFFFAOYSA-N |
CAS Registry2238821-31-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Lymphoma | Preclinical | CN | 19 Oct 2021 |